10-K: Regenerex Pharma Reports Full Year 2024 Results, Focuses on Wound Care Market Entry

Regenerex Pharma, a wound care company, reported its full year 2024 results, highlighting a significant net loss and ongoing efforts to launch its wound care products.

Summary

• Regenerex Pharma, a company focused on developing and marketing wound care products, filed its annual report for the fiscal year ended March 31, 2024.
• The company is developing three technologies for different types of wound conditions, including chronic, acute, and contaminated wounds.
• Regenerex's products are based on QBx technology, which aims to down-regulate proteases that impede wound healing.
• The company has acquired proprietary wound care formulations and has leased a plant and equipment in Tennessee.
• Regenerex plans to launch its sales initiative during the second quarter of its fiscal year ending March 31, 2025.
• The company is also developing managed care agreements with southeastern states and negotiating with distributors in the Middle East.
• For the year ended March 31, 2024, Regenerex reported a net loss of $3,543,827, compared to a net loss of $137,330 in the previous year.
• The company's primary sources of liquidity were notes payable of $123,844 and proceeds from the sale of common stock and warrants of $393,250.
• The company's independent auditor has raised substantial doubt about its ability to continue as a going concern.
• As of March 31, 2024, the company had 278,225,910 shares of common stock outstanding.

Sentiment

Score: 3

Explanation: The document highlights significant financial losses, a lack of revenue, and concerns about the company's ability to continue as a going concern. While there are positive aspects regarding the technology and market opportunity, the overall sentiment is negative due to the financial instability and operational risks.

Positives

• Regenerex has developed a unique wound care technology based on down-regulating proteases, which could provide a competitive advantage.
• The company has secured a manufacturing facility and equipment through a lease agreement.
• Regenerex is actively pursuing managed care agreements and international distribution partnerships.
• The company has secured trademark and patent rights for its wound care platform.
• The company has a clear plan to launch its sales initiative in the near future.

Negatives

• Regenerex reported a significant net loss of $3,543,827 for the year ended March 31, 2024.
• The company has no revenue to date.
• The company's auditor has raised substantial doubt about its ability to continue as a going concern.
• The company has a history of name changes and shifts in business focus.
• The company is dependent on a small management team.
• The company has limited funds and may need additional financing to execute its business plan.
• The company's internal controls over financial reporting were deemed ineffective as of March 31, 2024.

Risks

• The company faces competition from existing consumer product companies.
• Regenerex is an emerging growth company and may have reduced disclosure requirements.
• The company has a limited operating history and a lack of revenue.
• The company needs additional financing and has no commitments for it.
• The company may not be able to meet SEC filing requirements.
• The company is not diversified and is dependent on one business.
• The company may issue more shares, which could dilute existing shareholders.
• The company is dependent on its management team and consultants.
• The company may not be able to attract and retain qualified personnel.
• The company's securities are subject to penny stock regulations.
• The company's officers and directors own a substantial portion of its stock, which could control voting outcomes.
• The company will pay no foreseeable dividends in the future.
• The company's internal controls over financial reporting were deemed ineffective.

Future Outlook

The company expects to launch its sales initiative during the second quarter of its fiscal year ending March 31, 2025, and is actively seeking to raise additional debt and/or equity capital to add new products and/or services to commence material operations.

Management Comments

• Management believes that the company's unique technology will provide a distinct advantage over other companies in the wound care sector.
• Management is engaged in developing managed care agreements with southeastern states to manage their Medicaid wound care patients.
• Management is also in the process of negotiating with several distributors in various Middle Eastern countries to provide the company's products.

Industry Context

The wound care market is experiencing significant cost pressures, with the US government and payors seeking new approaches that address cost constraints and product performance. The fastest growing segment in the US wound market is Home Health and Nursing Homes due to the aging population, which aligns with Regenerex's initial market focus.

Comparison to Industry Standards

• The document states that there are no products currently available on the market that are successful in healing chronic, non-healing wounds through the down regulation of proteases, which is the basis of Regenerex's technology.
• This claim positions Regenerex as a potential leader in a specific niche of the wound care market, if the technology is proven effective.
• However, the document does not provide specific comparisons to other companies or products in terms of clinical trial results, market share, or financial performance.
• Without this information, it is difficult to assess Regenerex's competitive position relative to established players in the broader wound care industry, such as Smith+Nephew, 3M, or ConvaTec.

Related Party Transactions

• The company purchased assets from the company's current Chief Executive Officer (CEO) and Secretary/Treasurer.
• The company has entered into an agreement with Woundcare Labs, LLC, a party related to the CFO and CEO of the company, to lease a plant and to lease equipment in Tennessee.
• The company's Chief Financial Officer and the company's Chief Executive Office advanced $3,490 and $200 to the company during the years ended March 31, 2024 and 2023, respectively, to pay for operating expenses.
• During the years ended March 31, 2024 and 2023, the company's CFO and the company's CEO advanced the company monies for operating expenses in the amount of $120,000 and $40,500, respectively.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial losses and going concern issues.
• Employees, if any, may be impacted by the company's financial instability.
• Customers may benefit from the company's wound care products if they are successfully launched.
• Suppliers and creditors face risk due to the company's financial situation.

Next Steps

• The company plans to launch its sales initiative during the second quarter of its fiscal year ending March 31, 2025.
• The company will continue to develop managed care agreements with southeastern states.
• The company will continue to negotiate with distributors in the Middle East.
• The company will seek additional capital to fund its operations.

Key Dates

Keywords

wound care, chronic wounds, QBx technology, proteases, wound healing, medical devices, healthcare, FDA, Medicaid, home health, biotech, pharmaceuticals